{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:22:08Z","timestamp":1790007728939,"version":"4.0.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2007,2,26]],"date-time":"2007-02-26T00:00:00Z","timestamp":1172448000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2007,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>At the time of feasibility work and final design of the trial there was no randomised control trial evidence for the long-term risks and benefits of hormone replacement therapy. Observational studies had suggested that long term use of estrogen was likely to be associated, amongst other things, with reduced risks of osteoporosis and ischaemic heart disease and increased risks of breast and endometrial cancer. Concomitant use of progestogens had been shown to protect against endometrial cancer, but there were few data showing how progestogen might affect estrogen actions on other conditions. Disease specific risks from observational studies suggested that, overall, long-term HRT was likely to be beneficial. Several studies showed that mortality from all causes was lower in HRT users than in non-users. Some secondary cardiovascular prevention trials were ongoing but evidence was also required for a range of outcomes in healthy women. The WISDOM trial was designed to compare combined estrogen and progestogen versus placebo, and estrogen alone versus combined estrogen and progestogen. During the development of WISDOM the Women's Health Initiative trial was designed, funded and started in the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Randomised, placebo, controlled, trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The trial was set in general practices in the UK (384), Australia (94), and New Zealand (24). In these practices 284175 women aged 50\u201369 years were registered with 226282 potentially eligible. We sought to randomise 22300 postmenopausal women aged 50 \u2013 69 and treat for ten years. The interventions were: conjugated equine estrogens, 0.625 mg orally daily; conjugated equine estrogens plus medroxyprogesterone acetate 2.5\/5.0 mg orally daily; matched placebo. Primary outcome measures were: major cardiovascular disease, osteoporotic fractures, breast cancer and dementia. Secondary outcomes were: other cancers, all cause death, venous thromboembolism and cerebro-vascular disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The trial was prematurely closed during recruitment following publication of early results from the Women's Health Initiative. At the time of closure, 56583 had been screened, 8980 entered run-in, and 5694 (26% of target of 22,300) randomised. Those women randomised had received a mean of one year of therapy, mean age was 62.8 years and total follow-up time was 6491 person years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>The WISDOM experience leads to some simple messages. The larger a trial is the more simple it needs to be to ensure cost effective and timely delivery. When a trial is very costly and beyond the resources of one country, funders and investigators should make every effort to develop international collaboration with joint funding.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/1472-6874-7-2","type":"journal-article","created":{"date-parts":[[2007,2,27]],"date-time":"2007-02-27T08:12:29Z","timestamp":1172563949000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["The Women's international study of long-duration oestrogen after menopause (WISDOM): a randomised controlled trial"],"prefix":"10.1186","volume":"7","author":[{"given":"Madge R","family":"Vickers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannett","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W","family":"Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the WISDOM study team","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2007,2,26]]},"reference":[{"key":"98_CR1","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1056\/NEJM198711053171901","volume":"317","author":"DP Kiel","year":"1987","unstructured":"Kiel DP, Felson DT, Andersen JJ, Wilson PW, Moskowitz MA: Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study. N Eng J Med. 1987, 317: 1169-1174.","journal-title":"N Eng J Med"},{"key":"98_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0091-7435(91)90006-P","volume":"20","author":"MJ Stampfer","year":"1991","unstructured":"Stampfer MJ, Colditz GA: Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiological evidence. Prev Med. 1991, 20: 47-63. 10.1016\/0091-7435(91)90006-P.","journal-title":"Prev Med"},{"issue":"Suppl 13","key":"98_CR3","first-page":"87","volume":"103","author":"RL Theriault","year":"1996","unstructured":"Theriault RL: Hormone replacement therapy and breast cancer: an overview. Br J Ob Gyn. 1996, 103 (Suppl 13): 87-91.","journal-title":"Br J Ob Gyn"},{"key":"98_CR4","first-page":"521","volume":"54","author":"DW Cramer","year":"1979","unstructured":"Cramer DW, Knapp RC: Review of epidemiologic studies of endometrial cancer and exogenous estrogen. Obstet Gynecol. 1979, 54: 521-527.","journal-title":"Obstet Gynecol"},{"key":"98_CR5","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.7326\/0003-4819-117-12-1016","volume":"117","author":"D Grady","year":"1992","unstructured":"Grady D, Rubin SM, Pettiti DB, Fox Cs, Black D, Ettinger B, Ernster VL, Cummings SR: Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med. 1992, 117: 1016-1037.","journal-title":"Ann Intern Med"},{"key":"98_CR6","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/oxfordjournals.bmb.a072548","volume":"48","author":"TW Meade","year":"1992","unstructured":"Meade TW, Berra A: Hormone replacement therapy and cardiovascular disease. Br Med Bull. 1992, 48: 276-308.","journal-title":"Br Med Bull"},{"key":"98_CR7","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1056\/NEJM199109123251102","volume":"325","author":"MJ Stampfer","year":"1991","unstructured":"Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH: Postmenopausal estrogen therapy and cardiovascular disease: Ten year follow-up from the Nurses' Health Study. N Eng J Med. 1991, 325: 756-762.","journal-title":"N Eng J Med"},{"key":"98_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jama.1995.03520270033028","volume":"273","author":"The Writing Group for the PEPI trial","year":"1995","unstructured":"The Writing Group for the PEPI trial: Effects of estrogen\/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen\/Progestin Interventions (PEPI) trial. JAMA. 1995, 273: 199-208. 10.1001\/jama.273.3.199.","journal-title":"JAMA"},{"key":"98_CR9","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1136\/bmj.302.6788.1317","volume":"302","author":"HC Wilkes","year":"1991","unstructured":"Wilkes HC, Meade TW: Hormone replacement therapy in general practice: a survey of doctors in the MRC's general practice research framework. BMJ. 1991, 302: 1317-20.","journal-title":"BMJ"},{"key":"98_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1136\/bmj.312.7029.473","volume":"312","author":"Medical Research Council's General Practice Research Framework","year":"1996","unstructured":"Medical Research Council's General Practice Research Framework: Randomised comparison of oestrogen versus oestrogen plus progestogen hormone replacement therapy in women with hysterectomy. BMJ. 1996, 312: 473-478.","journal-title":"BMJ"},{"key":"98_CR11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0002-9343(91)80156-G","volume":"90","author":"JC Gallagher","year":"1991","unstructured":"Gallagher JC, Kable WT, Goldar D: Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med. 1991, 90: 171-178.","journal-title":"Am J Med"},{"key":"98_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/S0140-6736(96)03356-9","volume":"348","author":"M Tang","year":"1996","unstructured":"Tang M, Jacobs D, Stern Y, Marder K, Schofield P, Gurland B, Andrews H, Mayeux R: Effect of oestrogen during menopause on risk and age at outset of Alzheimer's disease. Lancet. 1996, 348: 429-432. 10.1016\/S0140-6736(96)03356-9.","journal-title":"Lancet"},{"key":"98_CR13","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1212\/WNL.48.6.1517","volume":"48","author":"C Kawas","year":"1997","unstructured":"Kawas C, Resnick S, Morrison A, Brookmeyer R, Corrada M, Zonderman A, Bacal C, Lingle DD, Metter C: A prospective study of estrogen replacement therapy and the risk of developing Alzheimer's disease. The Baltimore Longitudinal Study of Aging. Neurology. 1997, 48: 1517-1521.","journal-title":"Neurology"},{"issue":"21","key":"98_CR14","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1001\/archinte.1995.00430210075011","volume":"155","author":"A Paganini-Hill","year":"1995","unstructured":"Paganini-Hill A: The Benefits of Estrogen Replacement Therapy on Oral Health. Arch Int Med. 1995, 155 (21): 2325-2329. 10.1001\/archinte.155.21.2325.","journal-title":"Arch Int Med"},{"key":"98_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1902\/jop.1997.68.1.24","volume":"68","author":"JB Payne","year":"1997","unstructured":"Payne JB, Zachs NR, Reinhardt RA, Nummikoski PV, Patil KD: The association between estrogen status and alveolar bone density changes in postmenopausal women with a history of periodontitis. Periodontology. 1997, 68: 24-31.","journal-title":"Periodontology"},{"key":"98_CR16","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/0030-4220(92)90100-5","volume":"73","author":"A Forabosco","year":"1992","unstructured":"Forabosco A, Criscuolo M, Coukos G, Ucelli E, Weinstein R, Spinato S: Efficacy of hormone replacement therapy in postmenopausal women with oral discomfort. Oral Surgery, Oral Medicine, Oral Pathology. 1992, 73: 570-574. 10.1016\/0030-4220(92)90100-5.","journal-title":"Oral Surgery, Oral Medicine, Oral Pathology"},{"issue":"10","key":"98_CR17","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1002\/art.1780381017","volume":"38","author":"DT Felson","year":"1995","unstructured":"Felson DT, Zhang Y, Hannan MT, Naimark A, Weissman BN, Aliabadi P, Levy D: The incidence and natural history of knee osteoarthritis in the elderly. The Framingham Osteoarthritis Study. Arthritis Rheum. 1995, 38 (10): 1500-5. 10.1002\/art.1780381017.","journal-title":"Arthritis Rheum"},{"key":"98_CR18","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1001\/archinte.1996.00440170081009","volume":"156","author":"MC Nevitt","year":"1996","unstructured":"Nevitt MC, Cummings SR, Lane NE, Hochberg MC, Scott JC, Pressman AR, Genant HK, Cauley JA: Association of estrogen replacement therapy with the risk of osteoarthritis of the hip in elderly white women. Arch Intern Med. 1996, 156: 2073-2080. 10.1001\/archinte.156.18.2073.","journal-title":"Arch Intern Med"},{"key":"98_CR19","first-page":"21","volume":"4","author":"HA Risch","year":"1995","unstructured":"Risch HA, Howe GR: Menopausal hormone use and colorectal cancer in Saskatchewan: a record linkage cohort study. Cancer Epidemiology, Biomarkers & Prevention. 1995, 4: 21-28.","journal-title":"Cancer Epidemiology, Biomarkers & Prevention"},{"key":"98_CR20","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/bjc.1996.272","volume":"73","author":"E Fernandez","year":"1996","unstructured":"Fernandez E, La Vecchia C, D'Avanzo B, Franceschi S, Negri E, Parazzini F: Oral contraceptives, hormone replacement therapy and risk of colorectal cancer. Brit J Cancer. 1996, 73: 1431-1435.","journal-title":"Brit J Cancer"},{"key":"98_CR21","first-page":"289","volume":"92","author":"BE Klein","year":"1994","unstructured":"Klein BE, Klein R, Jensen SC, Ritter LL: Are sex hormones associated with age-related maculopathy in women? The Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 1994, 92: 289-295.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"98_CR22","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/S0161-6420(97)30198-5","volume":"104","author":"JM Benitez del Castillo","year":"1997","unstructured":"Benitez del Castillo JM, del Rio T, Garcia-Sanchez J: Effects of estrogen use on lens transmittance in postmenopausal women. Ophthamology. 1997, 104: 970-973.","journal-title":"Ophthamology"},{"key":"98_CR23","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/S0140-6736(96)07113-9","volume":"348","author":"E Daly","year":"1996","unstructured":"Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S: Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996, 348: 977-980. 10.1016\/S0140-6736(96)07113-9.","journal-title":"Lancet"},{"key":"98_CR24","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0140-6736(96)07114-0","volume":"348","author":"H Jick","year":"1996","unstructured":"Jick H, Derby LE, Myers MW, Vasilakis C, Newton KM: Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet. 1996, 348: 981-983. 10.1016\/S0140-6736(96)07114-0.","journal-title":"Lancet"},{"key":"98_CR25","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/S0140-6736(96)24041-3","volume":"348","author":"E Daly","year":"1996","unstructured":"Daly E, Vessey MP, Painter R, Hawkins MM: Case control study of venous thromboembolism risk in users of hormone replacement therapy. Lancet. 1996, 348: 1027-10.1016\/S0140-6736(96)24041-3.","journal-title":"Lancet"},{"key":"98_CR26","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1136\/bmj.314.7083.796","volume":"314","author":"SP Gutthann","year":"1997","unstructured":"Gutthann SP, Rodriguez LAG, Castellsague J, Oliart AD: Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ. 1997, 314: 796-800.","journal-title":"BMJ"},{"key":"98_CR27","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(96)07308-4","volume":"348","author":"F Grodstein","year":"1996","unstructured":"Grodstein F, Stampfer MJ, Goldhaber SZ, Manson JE, Colditz GA, Speizer FE, Willett WC, Hennekens CH: Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet. 1996, 348: 983-987. 10.1016\/S0140-6736(96)07308-4.","journal-title":"Lancet"},{"key":"98_CR28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1006\/gyno.1996.0315","volume":"63","author":"HA Risch","year":"1996","unstructured":"Risch HA: Estrogen replacement therapy and risk of epithelial ovarian cancer. Gynecol Oncol. 1996, 63: 254-257. 10.1006\/gyno.1996.0315.","journal-title":"Gynecol Oncol"},{"key":"98_CR29","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1017\/S0022215100135984","volume":"110","author":"D Strachan","year":"1996","unstructured":"Strachan D: Sudden sensorineural deafness and hormone replacement therapy. J Laryngol Otol. 1996, 110: 1148-1150.","journal-title":"J Laryngol Otol"},{"key":"98_CR30","first-page":"217","volume":"13","author":"M Cutolo","year":"1995","unstructured":"Cutolo M, Sulli A, Seriolo S, Accardo S, Masi AT: Estrogens, the immune response and autoimmunity. Clin Exp Rheumatology. 1995, 13: 217-226.","journal-title":"Clin Exp Rheumatology"},{"key":"98_CR31","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/0029-7844(95)00358-4","volume":"87","author":"B Ettinger","year":"1996","unstructured":"Ettinger B, Friedman GD, Bush T, Quesenberry CP: Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol. 1996, 87: 6-12. 10.1016\/0029-7844(95)00358-4.","journal-title":"Obstet Gynecol"},{"key":"98_CR32","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1056\/NEJM199706193362501","volume":"336","author":"F Grodstein","year":"1997","unstructured":"Grodstein F, Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M, Rosner B, Fuchs C, Hankinson SE, Hunter DJ, Hennekens CH, Speizer FE: Postmenopausal hormone therapy and mortality. N Eng J Med. 1997, 336: 1769-1775. 10.1056\/NEJM199706193362501.","journal-title":"N Eng J Med"},{"key":"98_CR33","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1136\/bmj.280.6206.44","volume":"280","author":"R Doll","year":"1980","unstructured":"Doll R, Peto R: Randomised controlled trials and retrospective controls. BMJ. 1980, 280: 44.","journal-title":"BMJ"},{"key":"98_CR34","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1177\/136218079600200309","volume":"1","author":"M Vickers","year":"1996","unstructured":"Vickers M: The MRC long-term randomised controlled trial of hormone replacement therapy: Background, design and objectives. J British Menopause Soc. 1996, 1: 9-13.","journal-title":"J British Menopause Soc"},{"key":"98_CR35","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0197-2456(97)00078-0","volume":"19","author":"The Women's Health Initiative Study Group","year":"1998","unstructured":"The Women's Health Initiative Study Group: Design of the Women's Health Initiative Clinical trial and Observational Study. Controlled Clinical Trials. 1998, 19: 61-109.","journal-title":"Controlled Clinical Trials"},{"issue":"7","key":"98_CR36","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1001\/jama.280.7.605","volume":"280","author":"S Hulley","year":"1998","unstructured":"Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, Vittinghoff E, for the Heart and Estrogen\/progestin Replacement Study Research Group: Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen\/progestin Replacement Study (HERS) Research Group. JAMA. 1998, 280 (7): 605-613. 10.1001\/jama.280.7.605.","journal-title":"JAMA"},{"key":"98_CR37","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1055\/s-0037-1614156","volume":"84","author":"E Hoibraaten","year":"2000","unstructured":"Hoibraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrom E, Sandset PM: Increased risk of recurrent venous thromboembolism during hormone replacement therapy. Results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thrombosis and Haemostasis. 2000, 84: 961-967.","journal-title":"Thrombosis and Haemostasis"},{"key":"98_CR38","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1056\/NEJMoa010534","volume":"345","author":"CM Viscoli","year":"2001","unstructured":"Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI: A clinical trial of estrogen -replacement therapy after ischemic stroke. New Eng J Med. 2001, 345: 1243-1249. 10.1056\/NEJMoa010534.","journal-title":"New Eng J Med"},{"key":"98_CR39","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.288.3.321","volume":"288","author":"Writing Group for the Women's Health Initiative Investigators","year":"2002","unstructured":"Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001\/jama.288.3.321.","journal-title":"JAMA"},{"key":"98_CR40","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1001\/jama.291.24.2947","volume":"291","author":"S Shumaker","year":"2004","unstructured":"Shumaker S, Legault C, Kuller L, Rapp S, Thal L, Lane D, Fillit H, Stefanick M, Hendrix S, Lewis C, Masaki K, Cocker L: Conjugated Equine Estrogens and Incidence of Probable Dementia and Mild Cognitive Impairment in Postmenopausal Women. Women's Health Initiative Memory Study. JAMA. 2004, 291: 2947-2958. 10.1001\/jama.291.24.2947.","journal-title":"JAMA"},{"key":"98_CR41","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMoa030311","volume":"348","author":"J Hays","year":"2003","unstructured":"Hays J, Ockene JK, Brunner RL, Shumaker SA, Brzyski RG, LaCroix AZ, Granek IA, Valanis BG, for the Womens Health Initiative investigators: Effects of estrogen plus progestin on health related quality of life. N Eng J Med. 2003, 348: 1839-54. 10.1056\/NEJMoa030311.","journal-title":"N Eng J Med"},{"key":"98_CR42","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1001\/jama.291.14.1701","volume":"291","author":"Women's Health Initiative Steering Committee","year":"2004","unstructured":"Women's Health Initiative Steering Committee: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative Randomised Controlled Trial. JAMA. 2004, 291: 1701-1712. 10.1001\/jama.291.14.1701.","journal-title":"JAMA"},{"key":"98_CR43","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/S0140-6736(97)08233-0","volume":"350","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1997","unstructured":"Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet. 1997, 350: 1047-1059. 10.1016\/S0140-6736(97)08233-0.","journal-title":"Lancet"},{"issue":"9382","key":"98_CR44","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0140-6736(03)14065-2","volume":"362","author":"Million Women Study collaborators","year":"2003","unstructured":"Million Women Study collaborators: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003, 362 (9382): 419-427. 10.1016\/S0140-6736(03)14065-2.","journal-title":"Lancet"},{"key":"98_CR45","doi-asserted-by":"publisher","first-page":"933","DOI":"10.7326\/0003-4819-133-12-200012190-00008","volume":"133","author":"F Grodstein","year":"2000","unstructured":"Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ: A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med. 2000, 133: 933-41.","journal-title":"Ann Intern Med"},{"key":"98_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/0003-4819-135-1-200107030-00003","volume":"135","author":"F Grodstein","year":"2001","unstructured":"Grodstein F, Manson JE, Stampfer MJ: Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study: a prospective, observational study. Ann Intern Med. 2001, 135: 1-8.","journal-title":"Ann Intern Med"},{"key":"98_CR47","first-page":"1","volume":"29","author":"Committee on Safety of Medicines","year":"2003","unstructured":"Committee on Safety of Medicines: HRT:update on the risk of breast cancer and long term safety. Current Problems in Pharmacovigilanc. 2003, 29: 1-3.","journal-title":"Current Problems in Pharmacovigilanc"},{"key":"98_CR48","unstructured":"The European Agency for the Evaluation of Medical Products: EMEA public statement on recent publications regarding hormone replacement therapy. 3 December 2003, [http:\/\/www.emea.europa.eu\/pdfs\/human\/press\/pus\/3306503en.pdf]"},{"key":"98_CR49","unstructured":"US Food and Drug Administration: The estrogen and progestin dilemma: new advice, labelling guidelines. [http:\/\/www.fda.gov\/fdac\/features\/2003\/203_estrogen.html]"},{"key":"98_CR50","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/13697130400001331","volume":"7","author":"AH MacLennon","year":"2004","unstructured":"MacLennon AH, Sturdee DW: WHI, WHI, WHI?. Climacteric. 2004, 7: 221-4. 10.1080\/13697130400001331.","journal-title":"Climacteric"},{"key":"98_CR51","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/j.1525-1497.2004.30281.x","volume":"19","author":"S Salpeter","year":"2004","unstructured":"Salpeter S: Mortality associated with hormone replacement therapy in younger and older women. J Gen Intern Med. 2004, 19: 791-804. 10.1111\/j.1525-1497.2004.30281.x.","journal-title":"J Gen Intern Med"},{"key":"98_CR52","first-page":"1833","volume":"15","author":"N Bellamy","year":"1988","unstructured":"Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt L: Validation study of WOMAC: a health ststus instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. The Journal of Rheumatology. 1988, 15: 1833-40.","journal-title":"The Journal of Rheumatology"},{"issue":"11","key":"98_CR53","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1053\/joca.2002.0838","volume":"10","author":"N Bellamy","year":"2002","unstructured":"Bellamy N, Campbell J, Haraoui B, Gerecz-Simon E, Buchbinder R, Hobby K, MacDermid JC: Clinimetric properties of the AUSCAN Osteoarthritis Hand Index: an evaluation of reliability, validity and responsiveness. Osteoarthritis Cartilage. 2002, 10 (11): 863-9. 10.1053\/joca.2002.0838.","journal-title":"Osteoarthritis Cartilage"},{"issue":"3","key":"98_CR54","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1177\/014662167700100306","volume":"1","author":"LS Radloff","year":"1977","unstructured":"Radloff LS: The CES-D Scale: A self-report depression scale for research in the general population. Applied Psychological Measurement. 1977, 1 (3): 385-401.","journal-title":"Applied Psychological Measurement"},{"key":"98_CR55","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1093\/gerona\/57.8.M532","volume":"57","author":"DB Petitti","year":"2002","unstructured":"Petitti DB: Prevalence of Dementia in Users of Hormone Replacement Therapy as Defined by Prescription. J Gerontol A Biol Sci Med Sci. 2002, 57: 532-538.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"98_CR56","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/BF00540019","volume":"5","author":"ME Hyland","year":"1996","unstructured":"Hyland ME, Sodergren SC: Development of a new type of global quality of life scale, and comparison of performance and preference for 12 global scales. Quality of Life Research. 1996, 5: 469-480. 10.1007\/BF00540019.","journal-title":"Quality of Life Research"},{"key":"98_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/08870449208404294","volume":"7","author":"M Hunter","year":"1992","unstructured":"Hunter M: The women's health questionnaire: A measure of mid-aged women's perceptions of their emotional and physical health. Psychology and Health. 1992, 7: 45-54.","journal-title":"Psychology and Health"},{"key":"98_CR58","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1080\/08870449508401947","volume":"10","author":"KL-M Liao","year":"1995","unstructured":"Liao KL-M, Hunter M, Weinman J: Health-related behaviours and their correlates in a general population sample of 45-year old women. Psychology and Health. 1995, 10: 171-184.","journal-title":"Psychology and Health"},{"key":"98_CR59","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol Group","year":"1990","unstructured":"EuroQol Group: EUROQOL: A new facility for the measurement of health related quality of life. Health Policy. 1990, 16: 199-208. 10.1016\/0168-8510(90)90421-9.","journal-title":"Health Policy"},{"key":"98_CR60","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1136\/bmj.313.7048.29","volume":"313","author":"AM Hickey","year":"1996","unstructured":"Hickey AM, Bury G, O'Boyle CA, Bradley F, O'Kelly FD, Shannon W: A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV\/AIDS. BMJ. 1996, 313: 29-33.","journal-title":"BMJ"},{"issue":"6","key":"98_CR61","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/00005650-199206000-00002","volume":"30","author":"JE Ware","year":"1992","unstructured":"Ware JE, Sherbourne C: The MOS 36-item short-form health survey (SF 36). 1. Conceptual framework and item selection. Medical Care. 1992, 30 (6): 473-483. 10.1097\/00005650-199206000-00002.","journal-title":"Medical Care"},{"key":"98_CR62","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4899-3115-3","volume-title":"Modelling Survival Data in Medical Research","author":"D Collett","year":"1994","unstructured":"Collett D: Modelling Survival Data in Medical Research. 1994, Chapman and Hall"},{"key":"98_CR63","first-page":"317","volume":"5","author":"M Vickers","year":"2002","unstructured":"Vickers M, Meade T, Darbyshire J: WISDOM: history and early demise \u2013 was it inevitable?. Climacteric. 2002, 5: 317-325.","journal-title":"Climacteric"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-7-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1472-6874-7-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-7-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1472-6874-7-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T17:27:48Z","timestamp":1630430868000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/1472-6874-7-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,2,26]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["98"],"URL":"https:\/\/doi.org\/10.1186\/1472-6874-7-2","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,2,26]]},"assertion":[{"value":"15 August 2006","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2007","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2007","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"2"}}